Skip to main content
. Author manuscript; available in PMC: 2019 Nov 20.
Published in final edited form as: Contraception. 2016 Mar 2;93(6):526–532. doi: 10.1016/j.contraception.2016.01.009

Table 1.

Participant demographics.

Copper IUD (n=67) Oral LNG 1.5 mg plus LNG IUD(n=121) P-value
N (%) N (%)
Age
18–24 years old 40 (60) 74 (61) 0.6
25–34 years old 25 (37) 47 (39)
35+ years old 1 (1) 0 (0)
UPI Timing
<24h 37 (55) 64 (53) 0.99
24–48 h 19 (28) 38 (31)
>48 h 11 (16) 19 (16)
#UPI in past 2 weeks
1 33 (49) 72 (60) 0.10
2 12 (18) 26 (21)
3 + 22 (33) 23 (19)
Days since LMP 17.1 (SD 8.2) 16.8 (SD 8.9) 0.82
Menstrual Cycle Length (days) 29.4 (SD 2.0) 28.8 (SD 2.0) 0.06
Race/Ethnicity
White 39 (59) 71 (60) 0.56
Hispanic 19 (29) 39 (33)
Other 8 (12) 9 (7)
Income
<$24,000 49 (74) 83 (69) 0.75
$24,000–$47,999 14 (21) 34 (28)
$48,000–$60,000 1 (2) 1 (1)
>$60,000 2 (3) 3 (2)
Insurance
No 37 (57) 69 (58) 0.94
Yes 28 (43) 51 (42)
Previous Pregnancy
No 35 (52) 55 (45) 0.37
Yes 32 (48) 66 (55)
Positive STI Screen 4 (7) 6 (7) 0.75
BMI
Underweight/Normal (< 25 kg/m2) 38 (60) 45 (39) 0.035
Overweight (25–29.9 kg/m2) 15 (24) 44 (38)
Obese (30+ kg/m2) 10 (16) 27 (23)

IUD, intrauterine device; LNG, levonorgestrel; UPI, unprotected intercourse; BMI, body mass index; LMP, last menstrual period; STI, sexually transmitted infection; SD, standard deviation. Percentage totals may not equal 100% due to rounding.